Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire January 27, 2023

Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023

Business Wire January 19, 2023

Gilead Sciences Again Named to Dow Jones Sustainability World Index

Accesswire January 5, 2023

Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope

Accesswire January 4, 2023

Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

Business Wire January 3, 2023

European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer

Business Wire January 3, 2023

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

GlobeNewswire December 27, 2022

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

Business Wire December 27, 2022

Gilead Sciences to Present at Upcoming Investor Conference

Business Wire December 23, 2022

Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Business Wire December 22, 2022

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV

Business Wire December 22, 2022

Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group

Accesswire December 21, 2022

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Business Wire December 20, 2022

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study

Business Wire December 19, 2022

Gilead Sciences: Latinas Contra Cancer Empowers Patients To Advocate for Change

Accesswire December 15, 2022

Gilead Sciences Again Named to Dow Jones Sustainability World Index

Business Wire December 12, 2022

New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Business Wire December 12, 2022

Three-Year Follow-Up Analysis of Kite's Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months

Business Wire December 12, 2022

Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite's Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma

Business Wire December 11, 2022

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis

Business Wire December 11, 2022